Location: Home
  • search
  • go
  • Relate News
  • 7/26/2022Mobile Health Applications for Depression in China: A Systematic Revie...
  • 7/22/2022Lilly and Triastek Tie Up to Explore the Application of 3D Printing Te...
  • 7/22/2022AbbVie Terminates Early-stage Study of I-Mab's Antibody lemzoparlimab...
  • 7/22/2022CDE Solicits Comments on the Draft Technical Guidelines for Drug Regis...
  • 7/22/2022CDE Issues the List of Reference Formulations for GQCE Studies (56th B...
  • 7/22/2022Two Chinese Biotechs Raise Millions for Shingles Vaccine Candidates to...
  • 7/22/2022Novaremed Enters License Pact with NeuroFront for Non-opioid Neuropath...
  • 7/22/2022Drug R&D and Product Registration News Digest July 2022 (3)
  • 7/21/2022WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapor...
  • 7/21/2022A Practical Review of the New Supporting Regulations of China's Anti-M...
  • 7/21/2022A Practical Review of the Amended Anti-Monopoly Law of China: Highligh...
  • 7/21/2022Draft "Regulation on Prohibition for Abuse of IP Rights to Exclude or ...
  • 7/20/2022China's Prospective Payment System: 3 Ways to Prepare
  • 7/20/2022Official Data: Chinese Pharma Growth Slows in H1/2022
  • 7/19/2022WuXi STA Opens a New Large Scale Continuous Manufacturing Plant
  • 7/19/2022China To Establish National Demonstration Zones For IPR Protection
  • 7/19/2022CNIPA: IP to Boost Bio-Economy Development in China
  • 7/19/2022WuXi AppTec Plans to Build a New Site in Singapore with Planned S$2B I...
  • 7/19/2022Brii Bio Announces Strategic Partnership with China Resources Pharma f...
  • 7/19/2022CDE Solicits Comments on the Draft Guidelines for Clinical Development...
  • 7/19/2022CDE Solicits Comments on the Draft FAQs for Rapid Reporting of Safety ...
  • 7/19/2022NHSA Issues New Notice to Further Strengthen Regulation of Medical Ser...
  • 7/18/2022Pharmanovia Expands Its Footprint in China With The Acquisition of Roc...
  • 7/18/2022Beijing's Top Health Official Fired for Corruption
  • 7/18/2022Unicycive Enters License Deal with Lee's Pharma for Renazorb in China ...
  • 7/18/2022Chugai's Osteoporosis Agent Edirol Launched in China
  • 7/18/2022NHC's 2021 Annual Health Sector Development Report (Full Summary)
  • 7/18/2022June Approvals See China's First Greenlight Based Entirely on Real-Wor...
  • 7/18/2022How China's Big Pharma Bet Could Change Intellectual Property Game
  • 7/18/2022Incidence and Mortality Trends of Nasopharynx Cancer from 1990 to 2019...
  • Page:77/719 Total number of articles:21546: [First][<<] [75] [76] [77] [78] [79] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group